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Abstract 
Background: Pharmacists are currently providing comprehensive medication management in the outpatient setting. However, there 
is little documented evidence demonstrating pharmacists are generating further improved health outcomes utilizing non-
pharmacologic support, such as fitness and nutrition counseling. The objective of this study is to determine if a pharmacist-led 
wellness program with medication management and lifestyle modifications through fitness and nutrition coaching can lead to 
improved biometric markers. 
Methods: The wellness program targeted corporate employees and was offered in a corporate headquarters' setting with an on-site 
workout facility. The program was expected to recruit approximately 15 patients into the wellness program consisting of two 
treatment arms. The standard group featured nutrition-based classes, medication therapy management and fitness education. The 
intervention group performed the standard group’s activities plus direct, supervised fitness training once weekly. Measured biometric 
markers were assessed at baseline, 3.5 months, and 7 months and included body mass index (BMI), waist circumference (WC), fasting 
blood glucose (FBG), systolic and diastolic blood pressure (SBP and DBP), and full lipid panel (TC, TG, HDL, and LDL).  
Results: Seventeen patients were enrolled in the study. The standard group (n = 11) and intervention group (n = 6) had relatively 
similar biometric markers at baseline. Seven total patients completed the study (4 from standard group, 3 from intervention group). 
The majority of biometric markers improved in both groups, and BP and LDL control was maintained for all who completed the study.  
Conclusion: These data suggest that a licensed pharmacist with certified personal trainer credentials may be capable of maintaining 
biometric markers at healthy levels and improving where necessary in an employee wellness program through one-on-one 
medication, fitness and nutrition support. Additional, large-scale research is needed to verify the clinical outcomes and feasibility in a 
larger group setting.  
 
 
Background  
Chronic medical conditions, such as cardiovascular disease, 
diabetes and obesity, represent some of the most common, 
most expensive and most preventable conditions in The 
United States.1 According to the Centers for Disease Control 
and Prevention (CDC) in 2012, about one-half of US adults are 
burdened with one or more chronic conditions.1 It is 
estimated that 47% of US adults have one or more risk factors 
for cardiovascular disease, such as uncontrolled high blood 
pressure, uncontrolled high LDL cholesterol or currently 
smoke. The American Diabetes Association in 2011 cited 8.3% 
of America, or 25.8 million American children and adults, 
have diabetes.2 Additionally, 79 million Americans were  
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found to have prediabetes, indicating a very large number of 
individuals are traveling down the path of diabetes and its 
associated complications.2 In 2012, costs associated with 
diabetes reached astronomical amounts, totaling $245 billion.  
In 2009-2010, it was estimated that approximately one-third, 
or 78 million Americans, were classified as obese (BMI > 30 
kg/m2).1 An even more concerning statistic reveals about one-
fifth of our nation's youth are obese (BMI > 95th percentile). 
This is resulting in earlier and more rapid onset of these 
aforementioned conditions, which significantly influences 
their health and well-being.  The increased incidence of these 
conditions can be attributed to what the CDC terms "health 
risk behaviors," which encompasses a lack of physical activity, 
inadequate nutrition, tobacco use and excessive ethanol 
consumption.1  Thus, it is evident from these statistics that 
additional interventions are warranted to manage and avert 
the development and progression of these conditions long-
term.    
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Former Surgeon General Dr. Richard H. Carmona indicated 
childhood weight gain is caused by an interplay of multiple 
variables, such as genetic, social, metabolic and 
environmental factors.3  He further states that, “the 
fundamental reason that our children are overweight is this: 
Too many children are eating too much and moving too 
little.”  It is reasonable to deduce the increased incidence and 
prevalence of these chronic conditions in adults may be for 
similar reasons. 
 
Physiologically, it has been shown that exercise causes an 
insulin-independent translocation of GLUT-4 receptors from 
the cytosol to the surface of skeletal myocytes.4  Additionally, 
there is data to support there are two separate "pools" of 
GLUT-4 receptors; one is translocated when the insulin-
signaling pathway is active, whereas the other is activated 
when skeletal muscle contracts.  Furthermore, inhibiting the 
insulin-signaling pathway and contracting skeletal muscle still 
resulted in GLUT-4 translocation in rats. This contraction-
induced pathway remains elevated for several hours after the 
cessation of exercise.5 Thus, in patients with Type 2 Diabetes 
Mellitus (T2DM) who exhibit some dysfunction in the insulin-
signaling pathway, exercise provides a viable physiologic 
strategy to increase glucose uptake into skeletal muscle via 
this separate pathway. 
 
A joint position statement from the American College of 
Sports Medicine and The American Diabetes Association in 
2010 cites numerous recommendations to circumvent the 
development of diabetes and how to optimally manage 
existing diabetes with exercise modalities.5 For prevention of 
diabetes, it is recommended that individuals participate in at 
least 2.5 hours per week of moderate to vigorous physical 
activity.  Individuals with existing diabetes are encouraged 
engage in aerobic exercise for 150 minutes per week, three 
days per week with no more than 2 consecutive days 
between bouts of aerobic activity.  Additionally, it is 
recommended individuals with T2DM engage in resistance 
training at least 2 to 3 days per week.  Also, there is data that 
support the combination of aerobic and resistance training 
with a qualified supervisor or personal trainer confers 
additional benefits than if each activity was performed on its 
own or in an unsupervised fashion.5 Thus, the incorporation 
of a personal trainer into a T2DM patient's care plan may be 
an effective strategy for managing their condition by ensuring 
proper exercise technique as well as maintaining 
accountability and motivation.  
 
The national guidelines for cardiovascular disease, diabetes 
and obesity recommend both pharmacologic as well as non-
pharmacologic options for chronic management.6,7,8,9  For the 
majority of guidelines, there are target goals for specific 
biometric markers that indicate whether a patient’s condition 
is adequately managed, for example, fasting blood glucose 
(FBG) < 130 mg/dL for individuals with diabetes.8  This 
represents a feasible and simple method of monitoring 
patient progress in the outpatient setting.  However, there is 
little documented evidence that pharmacists are generating 
further improved outcomes by utilizing a combination of 
pharmacologic and non-pharmacologic support.  
 
This study was developed to test the hypothesis that a 
pharmacist with personal trainer credentials (PPT) may have 
a unique expertise in being an on-site wellness consultant, 
capable of managing both pharmacologic and non-
pharmacologic options simultaneously at a single location 
while maintaining patient accountability. Therefore, the 
purpose of this study is to determine if a pharmacist-led 
wellness program with medication management and lifestyle 
modifications through fitness and nutrition can lead to 
improved biometric markers.  
 
Methods 
The PPT was a licensed pharmacist and a Certified Personal 
Trainer from the National Strength and Conditioning 
Association who practiced one day per week at a large 
grocery chain Division Office in Westerville, Ohio. Employees 
of the office were notified of the study via email and flyers, 
and were randomized into two treatment arms. The standard 
group had nutrition-based presentations given once monthly, 
a comprehensive medication review and fitness education. 
The intervention group had the standard group’s activities 
plus once-weekly personal training. The measured biometric 
markers of the study were systolic blood pressure (SBP), 
diastolic blood pressure (DBP), body mass index (BMI), waist 
circumference (WC), total cholesterol (TC), triglycerides (TG), 
high-density lipoprotein (HDL), low-density lipoprotein (LDL), 
and fasting blood glucose (FBG).  Inclusion criteria were based 
on an existing health coaching program within the employer 
group, which included patients with a BMI > 29 or BMI > 27 
with one or more of the following documented: FBG > 100 
mg/dL, BP > 120/80 mmHg, or LDL-C > 140 mg/dL. All 
participants were required to complete an exercise clearance 
form prior to participation to verify no current medical 
conditions would be exacerbated by physical activity. Patients 
were excluded if the patient's physician did not grant 
clearance to participate in the program. Formal feedback was 
not solicited, however, verbal/written feedback was accepted 
if offered during the study period. The authors planned for a 
study duration of approximately 7 months. A midpoint 
evaluation was scheduled to occur half-way through the 
study to assess progress.   
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Nutrition-based presentations included an initial 
visit/background, basics of nutrition, meal planning (given by 
a Registered Dietician), dining out/portion control/dieting, 
physical activity, importance of adequate protein intake, and 
physical activity. Each interactive class lasted 1-hour in length 
and was open to questions during and post-presentation. 
Intervention participants were instructed to engage in 150 
minutes of aerobic activity per week in addition to resistance 
training 2 to 3 times per week on non-consecutive days, with 
one of those sessions being with the PPT. Prescribed 
workouts were full-body in nature, emphasizing major upper 
and lower body push/pull movements.   
 
Cholesterol and glucose were measured with Alere 
Cholestech LDX analyzers. Descriptive statistics were used to 
denote changes over time and differences between groups 
and were analyzed with Microsoft Excel 2010. This study was 
approved by Ohio Northern University's Institutional Review 
Board and patient consents were obtained. 
 
Results  
Seventeen patients were recruited at baseline. Six individuals 
were randomly selected to be in the intervention group for 
this pilot study.  Randomization and recruitment results are 
noted in Figure 1. Both groups presented in a generally 
healthy state. Baseline characteristics can be found in Table 
1. Average baseline, midpoint and final biometric markers for 
the standard and intervention groups can be found in Table 2.  
Blood pressures and LDL cholesterol in both groups were 
well-controlled at baseline. Average BMI and WC were higher 
than recommended values (BMI > 30, WC > 40 inches for 
men, > 35 inches for women). Average lipid profiles in the 
standard group were generally healthy, but the intervention 
group had TG > 150mg/dL and HDL < 40mg/dL.  
 
The standard group at the midpoint evaluation experienced a 
decrease in BMI, WC, TG, LDL, and FBG.  An increase was seen 
in TC which may have been in part due to increased HDL. FBG 
remained in the normal fasting range. Out of the 11 patients 
in the standard group, four individuals chose not to continue 
participating in the program up to the midpoint evaluation.  
At the conclusion of the study, three more individuals were 
lost to follow-up, leaving a total of 4 individuals to be 
evaluated.  Formal assessment of rationale for declined 
participation was not accomplished; however, several 
patients informed the PPT that discontinuation was related to 
time constraints. The results were generally similar to the 
midpoint evaluation, with some markers improving slightly. 
After formal medication review, no medication changes were 
deemed necessary, but counseling was provided as clinically 
appropriate.  
 
The intervention group at the midpoint evaluation 
experienced a decrease in TG and LDL and slight increase in 
HDL. BP and FBG only slightly decreased. Weight 
measurements remained comparable to baseline. No 
dropouts occurred during the first half of the program. At the 
conclusion, three individuals dropped out; two were for non-
study related medical reasons, and the PPT was notified of 
their discontinuation. BP was maintained at levels similar to 
baseline. BMI and WC decreased from midpoint. TG, LDL and 
FBG continued to decrease, while HDL increased slightly 
compared to the midpoint (see Table 2). Similar to the 
standard group, no medication changes were deemed 
necessary, but counseling was provided as clinically 
appropriate. The final data analysis included two individuals 
with T2DM. The three individuals who completed the study 
conveyed both written and verbally a high level of 
satisfaction.  
 
Table 3 illustrates the difference between the baseline and 
final assessment, and average change of biometric markers 
for the individuals completing the study. For the intervention 
group, patients 1 and 3 have diabetes; patient 2 exhibited a 
lipid profile and FBG that were maintained within normal 
ranges. Two individuals in the standard group experienced, at 
face value, a substantial increase in SBP, however, these 
values were still within normal ranges. Similarly, patient 4 in 
the standard group experienced a substantial increase in TG, 
but this marker remained within normal limits through the 
duration of the study. BP and LDL remained controlled for all 
individuals who completed the study.  
 
Discussion 
Participant groups presented with generally controlled BP 
and lipids, but obesity was highly prevalent among this 
population. Lifestyle changes, specifically improved nutrition 
and increased exercise, would be anticipated to improve all of 
the studied biometric markers. Biometric markers improved 
in both groups within an expected margin given the study 
duration. One key difference between the two groups was 
the frequency of encounters with the PPT. The intervention 
group met approximately four days per month, whereas the 
standard group met once per month. Although statistical 
tests for analysis were not completed due to small sample 
size, trends for further improvement were shown in the 
intervention group as compared to the standard group.  
  
The three individuals in the intervention group subjectively 
reported a very high degree of satisfaction, improved sense 
of well-being, higher energy and increased productivity.  In 
contrast, very little feedback was given from the standard 
group. The intervention group also specifically cited the value 
of a weekly check-in. The partnership/relationship developed 
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with the PPT was exclusive to this group and may be a key 
reason why this group experienced more significant 
improvements in their health. Thus, the number of overall 
encounters with a PPT may impact several personal 
components of patient care, such as developing rapport, 
motivation and trust. This demonstrates that, albeit with a 
very small sample size, a PPT is capable of beginning and 
maintaining relationships while keeping individuals 
accountable and on-track to meet their health goals.  
 
The individuals in both groups often cited general reasons as 
to why they no longer wanted to participate, with the 
majority citing time constraints as a limiting factor. Two 
individuals in the intervention group cited medical reasons 
for not being able to complete the protocol that were non-
study related.  
 
A limitation of the study is the ability to generalize these 
conclusions to a larger population. The location was a single 
workplace that employed fewer than 150 individuals, not all 
of which would have met the inclusion criteria. Additionally, 
facilities limited the number of individuals that could exercise 
simultaneously. Patients were notified of the study via email 
and flyers, thus voluntarily decided to participate in the 
study.  The inability to impact a large number of individuals 
over a state-wide division or a nation-wide corporation is not 
feasible with a single practitioner at a single site. Thus, 
implementation into a massive, nation-wide corporation 
would require additional sites and providers to allow for the 
greatest possible impact.  It is uncommon for an individual to 
be licensed as both a pharmacist and personal trainer, 
therefore reproducibility may be more difficult than a model 
where the pharmacist did not require additional certification.  
 
Future research could investigate a similar model with a 
larger sample size and/or in related practice settings. 
Additionally, it would be beneficial to determine a method or 
technique to motivate individuals who may not possess a 
high degree of intrinsic motivation.  Also, it may be 
worthwhile to investigate if the magnitude of improvement 
could be greater in a population with worse baseline health 
and need for increased pharmacologic support. In this study, 
patients often had higher levels of motivation because of the 
voluntary nature of recruitment. Therefore, finding a viable 
strategy to recruit patients who lack motivation could be a 
worthwhile endeavor to improve employee health.  
 
Conclusion 
This was a small, exploratory study by design to determine 
the viability of a wellness model and its potential 
implementation in a workplace setting.  This specific model 
required a facility with direct patient access and fitness room 
with a combination of aerobic and resistance training options; 
however, very similar models could be developed with 
synergy for other worksites.  When facilities are available and 
a sufficient quantity of interested participants are available, 
not only is a PPT able to help improve biometric markers, but 
participants who received weekly intervention felt an 
improved sense of well-being, more energy and increased 
productivity.  Additional, large-scale research is warranted to 
verify the potential success of implementation within other 
workplace environments. 
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Figure 1: Randomization and Recruitment                
Table 1: Baseline Data 
Characteristic All participants 
(n=17) Standard  (n=11) Intervention  (n=6) Average age 48 (range: 29-63) 48.1 48.5 Gender M: 2 (12%) F: 15 (88%) M: 1 (6%) F: 10 (94%) M: 1 (17%) F: 5 (83%) Hypertension 9 (53%) 5 4 Diabetes 3 (18%) 0 3 Hyperlipidemia 4 (24%) 1 3 BMI > 30 13 (76%) 7 6     
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Final 
Midpoint 
Randomization 
Start n = 17 
Standard  
n = 11 
n = 7 
n = 4 
Intervention 
 n = 6 
n = 6 
n = 3 
Clinical Experiences PRACTICE-BASED RESEARCH 
  
Table 2: Average biometric markers collected during three collection points – Standard and Intervention groups 
Biometric 
markers 
(units) 
Standard group Intervention group 
Baseline 
(n=11) Midpoint (n=7) End  (n=4) Baseline (n=6) Midpoint (n=6) End  (n=3) 
SBP 
(mmHg) 
123.7 126.0 132 126.0 122.7 122.3 
DBP 
(mmHg) 
82.1 79.1 86.5 82.8 77.7 77.0 
BMI 
(kg/m2) 
32.6 31.0 30.9 38.1 38.2 35.5 
WC  
(inches) 
41.6 39.2 39.5 46.2 45.6 45.2 
TC   
(mg/dL) 
190.3 196.0 206.0 179.5 161.8 154.0 
TG   
(mg/dL) 
130.2 113.1 77.0 162.5 132.7 121.3 
HDL 
(mg/dL) 
50.9 59.6 65.0 34.7 36.0 38.0 
LDL 
(mg/dL) 
118.5 113.7 125.3 112.5 99.0 91.7 
FBG 
(mg/dL) 
95.5 94.4 100.5 113.7 112.2 106.0 
Number of 
dropouts 
N/A 4 7 N/A 0 3 
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Table 3: Standard and intervention group net changes from beginning to end. 
 “+” indicates an increase in value from baseline, “-“ indicates a decrease from baseline 
Biometric 
Marker 
(units) 
Standard Intervention  
Net ∆ 
Patient 
1 
Net ∆ 
Patient 
2 
Net ∆ 
Patient 
3 
Net ∆ 
Patient 
4 
Avg 
∆ 
Net ∆ 
Patient 
1 Net ∆ Patient 2 Net ∆ Patient 3 Avg ∆ SBP (mmHg) -8 +4 +26 +16 +9.5 +2 -10 -7 -5 DBP (mmHg) -14 +6 +10 +10 +3 -4 -1 -1 -2 BMI (kg/m2) -2 +0.5 -0.5 +1.2 -0.2 -1.2 -0.9 -1.8 -1.3 WC  (inches) +1.5 -4 +1 -2.5 -1 -5 0 -1.5 -2.2 TC   (mg/dL) +11 -15 -27 +10 -5.3 -27 -14 +17 -8 TG   (mg/dL) -14 -48 +2 +47 -3.3 -68 +17 -89 -47 HDL (mg/dL) -8 -3 +13 +0 +0.5 0 +1 +18 +6.3 LDL (mg/dL) +22 -2 -40 +0 -5 -13 -19 +16 -5.3 FBG (mg/dL) +1 -3 +12 -7 +0.8 -6 +3 -8 -3.7  
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